How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of percutaneous transluminal renal sympathetic denervation for resistant hypertension

    Closed for comments This consultation ended on at   Request commenting lead permission

    Additional information considered by IPAC

    Professional experts' opinions

    Expert advice was sought from consultants who have been nominated or ratified by their professional Society or Royal College. The advice received is their individual opinion and is not intended to represent the view of the society. The advice provided by professional experts, in the form of the completed questionnaires, is normally published in full on the NICE website during public consultation, except in circumstances but not limited to, when comments are considered voluminous, or publication would be unlawful or inappropriate.

    Four professional expert questionnaires for percutaneous transluminal renal sympathetic denervation for resistant hypertension were submitted and can be found on the NICE website.

    Patient commentators' opinions

    NICE's Public Involvement Programme was unable to gather patient commentary for this procedure.

    Company engagement

    A structured information request was sent to 2 companies who manufacture a potentially relevant device for use in this procedure. NICE received 2 completed submissions. These were considered by the IP team and any relevant points have been taken into consideration when preparing this overview.

    Issues for consideration by IPAC

    Ongoing trials:

    • Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE; NCT01534299). Germany. Observational (case-only). Estimated enrollment, n=5,000. Estimated study completion date, October 2027.

    • SPYRAL HTN-ON MED Study (NCT02439775). International. RCT. Actual enrollment, n=337. Estimated study completion date, July 2026.

    • SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects with Uncontrolled HTN (NCT05198674). US and Germany. Clinical trial (single group assignment). Estimated enrollment, n=1,200. Estimated study completion date, June 2027.